Syncom Formulation (India) (BOM:524470) Piotroski F-Score: 6 (As of Jul. 05, 2026) — Near Median


BOM:524470 Syncom Formulation (India) Ltd BOM:524470
88 GF Score
Price ₹14.23
GF Value ₹19.87
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Syncom Formulation (India) Piotroski F-Score?

Syncom Formulation (India) BOM:524470 -0.14% 88 Piotroski F-Score is 6 as of Jul. 05, 2026, which is at its 10-year median of 6.00. GuruFocus rates BOM:524470 with a GF Score™ of 88/100 and a GF Value™ of ₹19.87 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 979 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 79.26% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Syncom Formulation (India) has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Syncom Formulation (India)'s Piotroski F-Score or its related term are showing as below:

BOM:524470' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of Syncom Formulation (India) was 7. The lowest was 4. And the median was 6.

Syncom Formulation (India)  (BOM:524470) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Syncom Formulation (India) Piotroski F-Score Related Terms


Syncom Formulation (India) Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Syncom Formulation (India)'s Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syncom Formulation (India) Piotroski F-Score Chart

Syncom Formulation (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 5.00 7.00 6.00

Syncom Formulation (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 0.00 0.00 6.00

BOM:524470 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India) Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Piotroski F-Score falls into.


BOM:524470
88GF Score
Syncom Formulation (India) Ltd BOM:524470
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹764 Mil.
Cash Flow from Operations was ₹581 Mil.
Revenue was ₹4,892 Mil.
Gross Profit was ₹2,049 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (4132.809 + 5338.452) / 2 = ₹4735.6305 Mil.
Total Assets at the begining of this year (Mar25) was ₹4,133 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹3,304 Mil.
Total Current Liabilities was ₹1,037 Mil.
Net Income was ₹494 Mil.

Revenue was ₹4,650 Mil.
Gross Profit was ₹1,577 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (4046.64 + 4132.809) / 2 = ₹4089.7245 Mil.
Total Assets at the begining of last year (Mar24) was ₹4,047 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹2,700 Mil.
Total Current Liabilities was ₹593 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Syncom Formulation (India)'s current Net Income (TTM) was 764. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Syncom Formulation (India)'s current Cash Flow from Operations (TTM) was 581. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=764.38/4132.809
=0.18495411

ROA (Last Year)=Net Income/Total Assets (Mar24)
=494.346/4046.64
=0.12216209

Syncom Formulation (India)'s return on assets of this year was 0.18495411. Syncom Formulation (India)'s return on assets of last year was 0.12216209. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Syncom Formulation (India)'s current Net Income (TTM) was 764. Syncom Formulation (India)'s current Cash Flow from Operations (TTM) was 581. ==> 581 <= 764 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/4735.6305
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/4089.7245
=0

Syncom Formulation (India)'s gearing of this year was 0. Syncom Formulation (India)'s gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3303.654/1037.258
=3.18498773

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2699.676/593.107
=4.55175204

Syncom Formulation (India)'s current ratio of this year was 3.18498773. Syncom Formulation (India)'s current ratio of last year was 4.55175204. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Syncom Formulation (India)'s number of shares in issue this year was 943.679. Syncom Formulation (India)'s number of shares in issue last year was 932.728. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2048.99/4891.715
=0.41886946

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1576.773/4650.126
=0.33908178

Syncom Formulation (India)'s gross margin of this year was 0.41886946. Syncom Formulation (India)'s gross margin of last year was 0.33908178. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=4891.715/4132.809
=1.18362958

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4650.126/4046.64
=1.14913261

Syncom Formulation (India)'s asset turnover of this year was 1.18362958. Syncom Formulation (India)'s asset turnover of last year was 1.14913261. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Syncom Formulation (India) has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Syncom Formulation (India) (BOM:524470) has a Piotroski F-Score of 6 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Syncom Formulation (India) and its competitors. This is near median its historical median of 6.00. Over the past decade, Syncom Formulation (India)'s Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Syncom Formulation (India) ranks #203 out of 979 companies in the Drug Manufacturers industry, placing it in the top 20.7%.
Is Syncom Formulation (India)'s Piotroski F-Score too high?
Syncom Formulation (India)'s current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Syncom Formulation (India)'s value of 6 is 20% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #203 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Syncom Formulation (India) has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #203 out of 979 companies for Piotroski F-Score. This places Syncom Formulation (India) in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Syncom Formulation (India)'s value of 6 is 20% above this benchmark. Historically, Syncom Formulation (India)'s own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹19.87, compared to a current price of ₹14.23 — trading 28.4% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Syncom Formulation (India)'s overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Piotroski F-Score is 6 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹14.23 is trading 28.4% below its estimated GF Value™ of ₹19.87. GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.

Key valuation signals for BOM:524470:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ₹19.87 vs. price of ₹14.23 (28.4% below fair value)
  • GF Score™: 88/100 with 1 warning sign
  • Industry Position: 20% above the Drug Manufacturers median (#203 of 979)

No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Syncom Formulation (India) Business Description

Other Exchanges SYNCOMF:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
88GF Score

Get the complete analysis for BOM:524470

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹14.23
Price
₹19.87
GF Value